Episodic hyperhidrosis as the only clinical manifestation of neuromyotonia.
Gómez-Choco
M J
MJ
Service of Neurology, Hospital Clinic, Barcelona, Spain. gomezchoco@hotmail.com
Valls-Solé
J
J
Grau
J M
JM
Graus
F
F
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004576:Electromyography; D006801:Humans; D006945:Hyperhidrosis / Q000209:etiology* / Q000503:physiopathology*; D020386:Isaacs Syndrome / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology*; D008297:Male; D018908:Muscle Weakness / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000503:physiopathology; D019653:Myeloablative Agonists / Q000627:therapeutic use; D010525:Peripheral Nerves / Q000503:physiopathology; D010956:Plasmapheresis; D011241:Prednisone / Q000627:therapeutic use; D013545:Sweat Glands / Q000294:innervation / Q000503:physiopathology; D017779:Sympathetic Fibers, Postganglionic / Q000503:physiopathology; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D019653:Myeloablative Agonists; D003520:Cyclophosphamide; D011241:Prednisone